- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BEAM
Recent news which mentions BEAM
7 Best Cathie Wood Stocks for Your May 2023 Buy List
May 02, 2023
From InvestorPlace
From Motley Fool
The 3 Most Promising Gene Editing Stocks to Buy in 2023
April 28, 2023
From InvestorPlace
Cathie Wood Is Unstoppable With Tesla Stock – Defies Wall Street To Make Whopping $29M Purchase
April 26, 2023
From Benzinga
3 Stocks to Watch in April: Is it Time to Buy?
April 18, 2023
From InvestorPlace
7 Top Growth Stocks to Buy for the Next Decade
April 18, 2023
From InvestorPlace
From Benzinga
From InvestorPlace
From Benzinga
From InvestorPlace
3 Game-Changing Stocks to Buy in March
March 04, 2023
From Motley Fool
The Top 7 Growth Stocks in Biotech
March 03, 2023
From InvestorPlace
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
From Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
February 06, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
From Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
From InvestorPlace
5 Top Stocks for February
January 29, 2023
From Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
January 27, 2023
From Motley Fool
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
January 21, 2023
From Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
January 15, 2023
From Motley Fool
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
January 04, 2023
From Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
December 24, 2022
From Motley Fool
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
December 20, 2022
From Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know
December 20, 2022
Tickers
BEAM
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
December 20, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.